TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16940720

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 14974656

Group type: EXPERIMENTAL
Intervention: 0.25% bupivicaine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Normal saline control
Number of subjects: 164
Study: 11682660

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9002081

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula
Number of subjects: 45

Group type: COMPARATOR
Intervention: Whey predominant formula
Number of subjects: 45
Study: 8206188

Group type: COMPARATOR
Intervention: External subcutaneous insulin pumps (EXT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable programmable insulin pumps (IMP)
Number of subjects: 0
Study: 3305224

Group type: COMPARATOR
Intervention: Chemotherapy only (CT) - monthly courses of cytosine arabinoside (ARA‐C) alternatingly combined with daunorubicin or thioguanine or cyclophosphamide
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (CIT) - intradermal injections of 10(10) neuraminidase‐treated viable allogeneic blasts per immunization interspersed between CT courses
Number of subjects: 167
Study: 28833652

Group type: EXPERIMENTAL
Intervention: 5% topical vitamin C applied twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study: 27133311

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAPT) - aspirin plus clopidogrel plus cilostazol; cilostazol loading dose of 100 mg bid for 1 week
Number of subjects: 113

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel; no cilostazol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: TAPT in antiplatelet-naïve subgroup
Number of subjects: 113

Group type: COMPARATOR
Intervention: DAPT in antiplatelet-naïve subgroup
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: TAPT in antiplatelet-treated subgroup
Number of subjects: 113

Group type: COMPARATOR
Intervention: DAPT in antiplatelet-treated subgroup
Number of subjects: 113
Study: 24749639

Group type: EXPERIMENTAL
Intervention: Mothers of young infants
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nulliparous females
Number of subjects: 94
Study: 24469880

Group type: EXPERIMENTAL
Intervention: 150 mg ASA
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel
Number of subjects: 234
Study: 20451174

Group type: EXPERIMENTAL
Intervention: Laparoscopic suturing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Laparoscopic drills
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Open suturing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) drills
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Physical laparoscopic trainer
Number of subjects: 41
Study: 17535502

Group type: EXPERIMENTAL
Intervention: Demand-control model of job strain
Number of subjects: 60
Study: 16189315

Group type: EXPERIMENTAL
Intervention: Drained group (drain for 24 hours)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Undrained group (no drain)
Number of subjects: 552
Study: 12915835

Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg per day for 28 days) plus dexamethasone (0.15 mg/kg per day for 5 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Albendazole plus dexamethasone
Number of subjects: 123
Study: 10507210

Group type: EXPERIMENTAL
Intervention: 1% TiF4
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.5% TiF4
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.1% TiF4
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: APF
Number of subjects: 32

Group type: COMPARATOR
Intervention: NaF
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (de-ionised water)
Number of subjects: 32
Study: 8961912

Group type: EXPERIMENTAL
Intervention: Colchicine plus benzathine penicillin for 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colchicine alone
Number of subjects: 0
Study: 1933520

Group type: EXPERIMENTAL
Intervention: Plasmion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Haemaccel
Number of subjects: 54
Study: 7049709

Group type: EXPERIMENTAL
Intervention: supidimide 2 x 200 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: supidimide
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 6360575

Group type: EXPERIMENTAL
Intervention: Verapamil 160 mg bd
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg qd
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil bd
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil qd
Number of subjects: 12
Study: 30037361

Group type: EXPERIMENTAL
Intervention: Budesonide MDI 320 μg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Budesonide MDI 160 μg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 147
Study: 25829062

Group type: EXPERIMENTAL
Intervention: rotatable handle piece (rot-HP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: standard laparoscopic (fixed) handle piece
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: higher working height (WH)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: lower working height (WH)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: both rot-HP and standard handle
Number of subjects: 57
Study: 24886034

Group type: EXPERIMENTAL
Intervention: Computer-based working memory training for 45 minutes, 25 sessions over 5 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo version of the program, identical in duration but non-adaptive in difficulty
Number of subjects: 90
Study: 23023322

Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing (IUT) prior to surgery for SUI or MUI
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing (IUT)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Research question underlying proposed studies
Number of subjects: 176
Study: 20350429

Group type: EXPERIMENTAL
Intervention: Endotracheal lavage (2-3 times daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (no lavage)
Number of subjects: 58
Study: 18565596

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (250 mug)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15990777

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12431891

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program by outreach visitors lasting 21 months
Number of subjects: 62
Study: 10417667

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control vaccine (inactivated polio vaccine)
Number of subjects: 306
Study: 9395611

Group type: EXPERIMENTAL
Intervention: Intravenous homeopathic complex preparations containing Echinacea angustifolia D1 (study 1)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Intravenous homeopathic complex preparations containing Echinacea angustifolia D4 (study 5)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Oral alcoholic extracts of roots of E. purpurea (studies 2 and 3a)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Extract of E. pallida roots (study 3b)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Extract of E. purpurea herb (study 4)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (control groups)
Number of subjects: 134
Study: 1799918

Group type: EXPERIMENTAL
Intervention: bis-glycino iron II
Number of subjects: 38

Group type: COMPARATOR
Intervention: ferrous sulfate
Number of subjects: 38
Study: 7451778

Group type: EXPERIMENTAL
Intervention: Skin-blister fluid (SBF) taken from dual skin reactions 30 or 60 min after allergen injection
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Skin-blister fluid (SBF) taken from LCR areas 180 or 300 min after antigen testing
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High doses of SBF from untested skin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Similar volumes of autologous heparin-plasma or serum
Number of subjects: 17
Study: 29192549

Group type: EXPERIMENTAL
Intervention: AMP XR-OS (15 mL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Adderall XR (30 mg capsule)
Number of subjects: 42
Study: 30454883

Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fatty fish
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lean fish
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 30156314

Group type: EXPERIMENTAL
Intervention: Fosravuconazole L-lysine ethanolate (100 mg RVCZ, n = 101)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 153
Study: 27374360

Group type: EXPERIMENTAL
Intervention: Leukocyte-platelet rich fibrin (L-PRF) with allogenous bone graft
Number of subjects: 28

Group type: COMPARATOR
Intervention: Allogenous bone graft with resorbable collagen membrane
Number of subjects: 28
Study: 24496492

Group type: EXPERIMENTAL
Intervention: Bisection plus reaching task (BR‐task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisection task (B‐task)
Number of subjects: 0
Study: 22216840

Group type: EXPERIMENTAL
Intervention: HSV vaccine (20 μg of glycoprotein D from HSV‐2 with alum and 3‐O‐deacylated monophosphoryl lipid A as an adjuvant)
Number of subjects: 8323

Group type: EXPERIMENTAL
Intervention: HSV vaccine
Number of subjects: 8323

Group type: COMPARATOR
Intervention: Control vaccine (hepatitis A vaccine, 720 ELISA units)
Number of subjects: 8323
Study: 20713883

Group type: EXPERIMENTAL
Intervention: Celecoxib (NSAID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17390103

Group type: EXPERIMENTAL
Intervention: 0.5 mg lorazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.0 mg lorazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16298697

Group type: EXPERIMENTAL
Intervention: In-home, nurse-delivered, symptom-focused teaching/counseling intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison group (usual care)
Number of subjects: 41
Study: 12575567

Group type: EXPERIMENTAL
Intervention: Tongmai Yizhi capsule (TMYZC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydergine (control)
Number of subjects: 50
Study: 9396450

Group type: EXPERIMENTAL
Intervention: Time-frequency domain method (TF) using smoothed pseudo-Wigner-Ville transformation (SPWVT) for heart rate variability analysis during tilt.
Number of subjects: 0
Study: 7943782

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 44
Study: 2452123

Group type: EXPERIMENTAL
Intervention: 0.25 mg of rIFN‐gamma/m2 body surface administered daily for 28 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.10 mg of rIFN‐gamma administered daily for 28 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups (0.25 mg and 0.10 mg of rIFN‐gamma)
Number of subjects: 8
Study: 30736102

Group type: EXPERIMENTAL
Intervention: Tailored exercise protocol during hospitalization, 15 to 30 minutes daily, supervised by an exercise specialist.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group remained physically inactive during hospitalization.
Number of subjects: 42
Study: 26785098

Group type: EXPERIMENTAL
Intervention: Assault-injured youth
Number of subjects: 964

Group type: COMPARATOR
Intervention: Unintentionally injured youth
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Assault-injured youth with 1 previous psychiatric ED visit
Number of subjects: 964
Study: 26467316

Group type: EXPERIMENTAL
Intervention: Stories DVD + routine clinical treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine clinical treatment
Number of subjects: 300
Study: 23148280

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21170557

Group type: EXPERIMENTAL
Intervention: Selective amygdalohippocampectomy (SAH)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Temporal lobe resection (TLR)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Both SAH and TLR
Number of subjects: 179
Study: 19648168

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Interferon-alpha plus cytarabine
Number of subjects: 1106
Study: 17399871

Group type: EXPERIMENTAL
Intervention: Trapeziectomy alone (with no wiring)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Trapeziectomy with flexor carpi radialis suspension
Number of subjects: 65
Study: 14760660

Group type: EXPERIMENTAL
Intervention: VR training (ten repetitions of all six tasks on the Minimally Invasive Surgical Trainer‐Virtual Reality (MIST‐VR))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 16

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study: 11214135

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gastroscopy (Control)
Number of subjects: 40
Study: 9165565

Group type: EXPERIMENTAL
Intervention: 1-mg tablet
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1-mg/ml oral solution
Number of subjects: 26
Study: 8222874

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg three times daily for 10-21 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Erythromycin base (EB) 500 mg three times daily for 10-21 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Erythromycin base (EB)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both EA and EB
Number of subjects: 57
Study: 3517712

Group type: EXPERIMENTAL
Intervention: Danazol therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30989339

Group type: EXPERIMENTAL
Intervention: Cementless standard femoral stems (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cementless short stems (Group B)
Number of subjects: 50
Study: 28657697

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication (MED)
Number of subjects: 124
Study: 27631248

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (conventional stroke rehabilitation program only)
Number of subjects: 41
Study: 24831764

Group type: EXPERIMENTAL
Intervention: Open irrigated tip catheter - Surround Flow™ (N=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8-mm-tip catheter (N=30)
Number of subjects: 60
Study: 21782351

Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 73
Study: 19767322

Group type: EXPERIMENTAL
Intervention: SMS diaries
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Paper diaries
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Online diaries
Number of subjects: 72

Group type: COMPARATOR
Intervention: Retrospective questionnaire
Number of subjects: 72
Study: 18281662

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1,000 mg/m(2) on days 1, 8, and 15 every 28 days
Number of subjects: 153

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m(2) every 28 days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 153
Study: 15813409

Group type: EXPERIMENTAL
Intervention: Automated accelerometry-based system for estimating initial contact (IC) and terminal contact (TC) timing
Number of subjects: 18
Study: 12646750

Group type: EXPERIMENTAL
Intervention: Oral administration of 600 mg levofloxacin plus five topical instillations before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical and oral administration of levofloxacin
Number of subjects: 0
Study: 10676545

Group type: EXPERIMENTAL
Intervention: Teaching staff development intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teaching practices
Number of subjects: 0
Study: 8686718

Group type: EXPERIMENTAL
Intervention: Oral antibiotic treatment (ciprofloxacin and rifampin)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous antibiotic treatment (oxacillin or vancomycin plus gentamicin)
Number of subjects: 85
Study: 8446254

Group type: EXPERIMENTAL
Intervention: Cefodizime (5 x 2 g intravenously, n = 10)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (960 mg orally b.i.d., n = 8)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 23
Study: 3785783

Group type: EXPERIMENTAL
Intervention: Radiation therapy (4500-5000 rad tumor dose in five to 6.5 weeks bilaterally to the groins and midplane of the pelvis)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pelvic node resection
Number of subjects: 114
Study: 31653175

Group type: EXPERIMENTAL
Intervention: Medication effect score
Number of subjects: 263
Study: 31479411

Group type: EXPERIMENTAL
Intervention: Lines
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dashed
Number of subjects: 10

Group type: COMPARATOR
Intervention: Corners
Number of subjects: 10
Study: 29447787

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Aspirin plus P2Y12 inhibitor (DAPT)
Number of subjects: 3000
Study: 27061246

Group type: EXPERIMENTAL
Intervention: Patients with PD/A
Number of subjects: 71

Group type: COMPARATOR
Intervention: Comparison group without an axis I disorder
Number of subjects: 71
Study: 24195609

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR) for 6 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (A or B, not specified)
Number of subjects: 39
Study: 21457605

Group type: EXPERIMENTAL
Intervention: CBT-group
Number of subjects: 11

Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 11
Study: 19480887

Group type: EXPERIMENTAL
Intervention: Families and Schools Together (FAST) program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (ongoing school services)
Number of subjects: 67
Study: 17173219

Group type: EXPERIMENTAL
Intervention: Metronidazole for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with metronidazole and azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15209319

Group type: EXPERIMENTAL
Intervention: Long distance group (36 km)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Short distance group (24 km)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (30 km)
Number of subjects: 21
Study: 11397720

Group type: EXPERIMENTAL
Intervention: Inogatran (low‐molecular‐mass direct thrombin inhibitor)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Inogatran
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 320
Study: 9418683

Group type: EXPERIMENTAL
Intervention: Dong quai
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 8494138

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 2967187

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10-20 mg o.d.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nifedipine SR 20-40 mg b.i.d.
Number of subjects: 59
Study: 31228189

Group type: EXPERIMENTAL
Intervention: alert-based computerized decision support (CDS)
Number of subjects: 458

Group type: COMPARATOR
Intervention: no notification (control)
Number of subjects: 458
Study: 28329231

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 112
Study: 26404105

Group type: EXPERIMENTAL
Intervention: Modified pre‐surgical nasoalveolar moulding (PNAM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hotz's plate
Number of subjects: 32
Study: 24948104

Group type: EXPERIMENTAL
Intervention: Herbal shampoo (Acorus calamus, Phyllanthus emblica, Zanthoxylum limonella)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbaryl shampoo (0.6% w/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Malathion shampoo (1.0% w/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial shampoos (Babi Mild Natural' N Mild, Johnson's baby shampoo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herbal shampoos (in vivo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemical shampoos (in vivo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial shampoos (in vivo)
Number of subjects: 0
Study: 22755347

Group type: EXPERIMENTAL
Intervention: Primary Closure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed Primary Closure
Number of subjects: 100
Study: 20686410

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment (5-day course given monthly for 8 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19065860

Group type: EXPERIMENTAL
Intervention: Congenitally blind participants
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normally sighted participants
Number of subjects: 3

Group type: COMPARATOR
Intervention: Late-onset blind participants
Number of subjects: 3
Study: 15988425

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.2 mg/kg bolus followed by 0.5 mg/kg/hour for 2 hours)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (normal-saline infusion)
Number of subjects: 68
Study: 12920976

Group type: EXPERIMENTAL
Intervention: Oil mixture supplemented (50% extra virgin olive oil and 50% soybean oil)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 14